Claims
- 1. A method for modulating the expression of Notch ligands on antigen presenting cells, comprising contacting the antigen presenting cells with a composition comprising at least one component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 2. The method of claim 1, wherein the antigen presenting cells are dendritic cells.
- 3. A method for modifying an immune response to an antigen in a subject, comprising administering to the subject a composition comprising at least one component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 4. A method for stimulating infectious tolerance to an antigen in a subject, comprising administering to the subject a composition comprising at least one component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 5. A method for treating a disorder characterized by the presence of an abnormal immune response in a subject, the method comprising administering to the subject a composition comprising at least one component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 6. A method for modulating Notch signaling in a population of cells, comprising contacting the cells with a composition comprising at least one component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 7. A method for modulating Notch signaling in a population of cells, comprising contacting the cells with a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of:
(a) SEQ ID NO: 27-52; (b) sequences encoded by a sequence of SEQ ID NO: 1-26; (c) sequence having at least 75% identity to a sequence of SEQ ID NO: 27-52; and (d) sequences having at least 90% identity to a sequence of SEQ ID NO: 27-52.
- 8. A method for modulating Notch signaling in a population of cells, comprising contacting the cells with a composition comprising a component selected from the group consisting of:
(a) delipidated and deglycolipidated M. smegmatis cells; and (b) delipidated and deglycolipidated M. tuberculosis cells.
- 9. A method for modulating expression of a Notch signaling gene in a population of cells, comprising contacting the cells with a composition comprising a component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 10. The method of claim 9, wherein the Notch signaling molecule is selected from the group consisting of: Notch1, Notch2, Notch3, Notch4, Deltex, Jagged-1, Jagged-2, Delta-like 1, Delta-like 3, HES-1, HERP1, HERP2, Lunatic Fringe, Manic Fringe, Radical Fringe, Numb, MAML1 and RBP-Jkappa.
- 11. A method for modulating expression of a Toll-like receptor gene in a population of cells, comprising contacting the cells with a composition comprising a component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 12. A method for modulating Notch signaling in a population of cells, comprising contacting the cells with a composition comprising peptidoglycan.
- 13. A method for modulating Toll-like receptor signaling in a population of cells, comprising contacting the cells with a composition comprising peptidoglycan.
- 14. A method for modulating Toll-like receptor signaling in a population of cells, comprising contacting the cells with a composition comprising a component selected from the group consisting of:
(a) inactivated M. vaccae cells; (b) delipidated and deglycolipidated M. vaccae cells; (c) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (g) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (h) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (i) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 60/308,446, filed Jul. 26, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60308446 |
Jul 2001 |
US |